

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Andrew et al.	Examiner:	Regina M. DeBerry
Serial No.:	10/614,599	Group Art Unit:	1647
Filed:	JULY 7, 2003	Docket No.:	11669.191USC1
Confirmation No.:	7759	Customer No.:	23552
Title:	WNT-Regulated Cytokine-Like Polypeptide and Nucleic Acids Encoding Same		

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(c))

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted before the mailing of a first Office Action after the filing of a Request for Continued Examination under 37 C.F.R. § 1.114 or a CPA under 37 C.F.R. § 1.53(d). Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. § 1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked


as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.

Respectfully submitted,

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, Minnesota 55402-0903
(612) 332-5300

Date: August 27, 2007


Katherine M. Kowalchyk

Reg. No. 36,848

23552

PATENT TRADEMARK OFFICE

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)			Docket Number: 11669.191USC1	Application Number: 10/614,599
			Applicant: ANDREW ET AL.	
			Filing Date: 07/07/2003	Group Art Unit: 1632

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
	NCBI Blast 2 Sequences Results Version BLASTP 2.2.17 (Aug. 19, 2007), http://www.ncbi.nlm.nih.gov/blast/bl2seq/wblast2.cgi?0					
	Hakonarson et al., "Association Between IL-1 β /TNF- α -Induced Glucocorticoid-Sensitive Changes in Multiple Gene Expression and Altered Responsiveness in Airway Smooth Muscle", <i>Am. J. Respir. Cell Mol. Biol.</i> , 25:761-771 (2001)					
	Smirnov et al., "Global Gene Expression Profiling of Circulating Tumor Cells", <i>Cancer Res.</i> , 65(12):4993-4997 (2005)					

23552

PATENT TRADEMARK OFFICE

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	